Aaron Ortega 9/17/24 Aaron Ortega 9/17/24

Maximizing Croptober: Essential Cannabis Inventory Management Practices for Retailers

Aaron Ortega 9/17/24 Aaron Ortega 9/17/24

Dealing with the Post-Croptober Inventory Glut: Strategies for Managing Excess Stock

Aaron Ortega 9/10/24 Aaron Ortega 9/10/24

Key Inventory Management Metrics to Optimize Dispensary Inventory for Croptober

Aaron Ortega 9/10/24 Aaron Ortega 9/10/24

Leveraging Cannabis Inventory Forecasting Software for Croptober Success

Aaron Ortega 9/3/24 Aaron Ortega 9/3/24

Unlocking the Power of FlyWheel’s Days of Items Remaining Report: A Retailer’s Guide to Smarter Inventory Management

Aaron Ortega 7/9/24 Aaron Ortega 7/9/24

Mastering Retail Success: Enhancing Brand Performance with Data-Driven Insights

Vasi Katris 5/16/24 Vasi Katris 5/16/24

Deciphering Data: Unveiling 4/20/2024 Insights

As the cannabis industry continues to grow and evolve, 4/20 serves as a pivotal moment for retailers to analyze trends and glean insights into consumer preferences. Recently, Mike Hosty, Customer Success & Training Specialist at 240 Logistics, hosted a Post-420 Webinar where he reviewed the data from 4/20/2024, explored trends and insights, and highlighted upcoming FlyWheel features intended to revolutionize the way cannabis dispensaries leverages their inventory and labor.

Vasi Katris 5/6/24 Vasi Katris 5/6/24

The Current State of Cannabis Logistics

The cannabis industry, with its complex state-by-state regulations and high operational costs, often resembles the daunting task of "building the plane while flying it." This blog examines the fragmented cannabis logistics landscape, highlighting the reliance on outdated technology, varied market regulations, and supply chain inefficiencies. It also introduces 240Logistics' FlyWheel™ software, a game-changing solution designed to streamline operations and reduce costs across the cannabis supply chain.

Vasi Katris 5/1/24 Vasi Katris 5/1/24

Cannabis Rescheduling: A Historic Leap Forward

The DEA's recommendation to reclassify cannabis as a Schedule III substance represents a historic change in federal policy, potentially easing regulatory and tax burdens for the industry. This shift aims to enhance medical research, increase mainstream acceptance, and stimulate industry growth by addressing legal and societal stigmas.